GlassScriptPhysician profile
Marc E Mccollaum
NPI 1871545046
$5,124.20
in general payments reported to CMS, 2019-2025
30 companies · $1,315 in 2025
The $1,315 reported for 2025 was more than what 87% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $951 · 2022: $1,256 · 2023: $924 · 2024: $679 · 2025: $1,315.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,918.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,917.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $800.07 | 2021-2024 | |
| Madrigal Pharmaceuticals | $638.61 | 2025 | Rezdiffra |
| Novo Nordisk INC | $578.79 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $554.13 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $330.92 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Indivior INC. | $310.37 | 2022-2024 | Sublocade |
| Abbvie INC. | $283.22 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $229.84 | 2023-2024 | Xarelto |
| Alnylam Pharmaceuticals INC. | $194.27 | 2022-2023 | Onpattro, Amvuttra |
| Abbott Laboratories | $188.33 | 2021-2023 | Freestyle Libre 2 |
| Teleflex LLC | $141.89 | 2022 | |
| Neurocrine Biosciences, INC. | $135.71 | 2025 | |
| Corcept Therapeutics | $124.98 | 2025 | Korlym |
| Tandem Diabetes Care, INC. | $123.64 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Amgen INC. | $122.16 | 2021-2023 | Otezla, Repatha |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $61.79 | 2021-2023 | Tymlos |
| Exact Sciences Corporation | $47.66 | 2023-2024 | Cologuard Collection Kit |
| Mannkind Corporation | $46.38 | 2021 | |
| Glaxosmithkline, LLC. | $24.83 | 2021 | |
| Amarin Pharma, INC. | $23.65 | 2021 | |
| Galderma Laboratories, L.P. | $22.59 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.49 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $16.93 | 2021 | |
| Medtronic, INC. | $16.54 | 2025 | Minimed 780g |
| Antares Pharma, INC. | $16.09 | 2021 | |
| Dexcom, INC. | $15.68 | 2022 | |
| Philips North America LLC | $15.45 | 2025 | Vest Therapy Und |
| Nestle Healthcare Nutrition INC. | $15.29 | 2022 | |
| Currax Pharmaceuticals LLC | $12.30 | 2022 | |
| Sanofi-Aventis U.S. LLC | $11.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Mccollaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.